on December 21, 2006
Published online before print December 21, 2006, doi: 10.1161/01.ATV.0000255952.47980.c2
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 25, 2006
Accepted on November 20, 2006
Aortic Valve Calcification. Determinants and Progression in the Population
David Messika-Zeitoun ;
From the Divisions of Cardiovascular Diseases and Internal Medicine (D.M.-Z., V.T.N., J.M., A.J.T., M.E.-S.), Radiology (P.F.S., J.F.B.), Hypertension (S.T.T.), and Biostatistics (C.S.), Mayo Clinic, Rochester, Minn; and Epidemiology (L.F.B., P.A.P.), University of Michigan, Ann Arbor.
* To whom correspondence should be addressed. E-mail: sarano.maurice{at}mayo.edu.
Background--Aortic valve calcification (AVC) is considered degenerative. Recent data suggested links to atherosclerosis or coronary disease (CAD).
Methods and Results--AVC and coronary artery calcifications (CAC) were prospectively assessed by Electron-Beam-Computed-Tomography in 262 population-based research participants 
60 years. AVC was frequent (27%) with aging (P<0.01) and in men (P<0.05). AVC was associated with diabetes, hypertension, higher body-mass-index, and serum glucose (all P<0.05). AVC was a marker of higher prevalence (P<0.01) and severity of CAD (CAC score: 441±802 versus 265±566, P<0.05) independently of age. After follow-up of 3.8±0.9 years, AVC score increased (94±271 versus 54±173, P<0.01, +11±32 U/year), faster with higher baseline AVC score (P<0.01). Compared with participants remaining free of AVC, de novo acquisition of AVC was associated with higher LDL-cholesterol (141±31 versus 121±27 mg/dL, P<0.05) and faster CAC progression (+78±87 versus +28±47 U/year, P<0.05). In multivariate analysis, LDL-cholesterol independently determined AVC acquisition while higher baseline AVC scores determined faster progression of existing AVC.
Conclusion--In the population, AVC is frequent with aging and atherosclerotic risk factors. AVC is a marker of subclinical CAD. AVC is progressive, appearing de novo with progressive atherosclerosis whereas established AVC progresses independently of atherosclerotic risk factors and faster with increasing initial AVC loads.
This article has been cited by other articles:
 |
|
 |
|
  M. Bhakta, C. Bruce, D. Messika-Zeitoun, L. Bielak, P. F. Sheedy, P. Peyser, and M. Sarano Oral Calcium Supplements Do Not Affect the Progression of Aortic Valve Calcification or Coronary Artery Calcification J Am Board Fam Med, November 1, 2009; 22(6): 610 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Sareyyupoglu, T. M. Sundt III, H. V. Schaff, M. Enriquez-Sarano, K. L. Greason, R. M. Suri, H. M. Burkhart, S. J. Park, J. A. Dearani, R. C. Daly, et al. Management of mild aortic stenosis at the time of coronary artery bypass surgery: should the valve be replaced? Ann. Thorac. Surg., October 1, 2009; 88(4): 1224 - 1231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Dumesnil, P. Pibarot, and B. Carabello Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment Eur. Heart J., September 8, 2009; (2009) ehp361v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Miller, R. M. Weiss, K. M. Serrano, R. M. Brooks II, C. J. Berry, K. Zimmerman, S. G. Young, and D. D. Heistad Lowering Plasma Cholesterol Levels Halts Progression of Aortic Valve Disease in Mice Circulation, May 26, 2009; 119(20): 2693 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yang, D. A. Fullerton, X. Su, L. Ao, J. C. Cleveland Jr, and X. Meng Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of Toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J. Am. Coll. Cardiol., February 10, 2009; 53(6): 491 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vahanian, B. Iung, L. Piérard, R. Dion, and J. Pepper CHAPTER 21 Valvular Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Miller, Y. Chu, R. M. Brooks, W. E. Richenbacher, R. Pena-Silva, and D. D. Heistad Dysregulation of Antioxidant Mechanisms Contributes to Increased Oxidative Stress in Calcific Aortic Valvular Stenosis in Humans J. Am. Coll. Cardiol., September 2, 2008; 52(10): 843 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Jassal, J. W. Tam, K. M. Bhagirath, I. Gaboury, R. A. Sochowski, J. G. Dumesnil, P. J. Giannoccaro, J. Jue, A. S. Pandey, C. D. Joyner, et al. Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study Eur. Heart J., June 2, 2008; 29(12): 1542 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. I. Michelena, V. A. Desjardins, J.-F. Avierinos, A. Russo, V. T. Nkomo, T. M. Sundt, P. A. Pellikka, A. J. Tajik, and M. Enriquez-Sarano Natural History of Asymptomatic Patients With Normally Functioning or Minimally Dysfunctional Bicuspid Aortic Valve in the Community Circulation, May 27, 2008; 117(21): 2776 - 2784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Sigrist, M. W. Taal, P. Bungay, and C. W. McIntyre Progressive Vascular Calcification over 2 Years Is Associated with Arterial Stiffening and Increased Mortality in Patients with Stages 4 and 5 Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1241 - 1248. [Abstract] [Full Text] [PDF]
|
|